Parameter
| Biomarker | PD-L1 | Full name | Programmed death-ligand 1 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prediction and diagnosis of immunotherapy efficacy | ||
| Disease | Esophageal Carcinoma | Disease Subtypes | / | ||
| Organ | Esophagus | Test Sample / Technology Platform | Tissue (IHC, SP263 assay) | ||
| Pathobiological Mechanisms | Combined with PD-1, it inhibits the activation of T cells and induces their apoptosis, helping tumor cells to evade immune surveillance. Its expression level directly affects the therapeutic effect of immune checkpoint inhibitors | ||||
| Clinical Availability Status | Clinical application/guideline recommendation: CPS and TAP scores have been used as core markers for predicting the efficacy of immunotherapy in ESCC, and are commonly used evaluation criteria | ||||
| Notes and Dynamics | CPS and TAP score are the key biomarkers for ESCC immunotherapy, and their combination with other biomarkers can improve the accuracy of efficacy prediction | ||||